Aspen Biosciences has continued to grow over the last quarter with the addition of 7 new team members, to help with the explosive demand for custom applications, and integrated systems in the drug discovery and diagnostics industries. These new team members bring the company size up to 70. Throughout this year, the Aspen Biosciences teams have also made meaningful improvements to existing products such as Pharm2Market and Pipeline while beginning development on Delos, a new application coming soon to the Biotechnology industry.
Pharm2Market: the business intelligence for biotechs platform continues to increase the numbers of unique visitors and subscribers. This business intelligence platform is designed specifically for pharmaceutical startup companies, investors and biotech service providers looking to connect with each other. Use this link to try this application for free. SDEE members receive a $10 discount when using this coupon code: SDEE21.
This year’s improvements include: performance updates, Apple iOS platform support, and improved querying capabilities. Data on biotech communities in the RTP area and in the UK will be released in 2022.
Pipeline: is a unique application designed to orchestrate the process of drug discovery (from target selection, to project planning, assay management and inventory). The development team continues to work with early access customers on the 2.0 release of the software, due in March.
Pipeline System Architecture:
Delos: collaborations between biopharmaceutical companies are a key inflection point in the process of getting new medicines from the bench to the bedside. A key missing piece to the puzzle, which Delos is designed to fill, has been the lack of software to manage the process of generating, curating and publishing reports in support of collaborations.
Delos Architecture:
If you would like to participate in our Early Access Programs, or need technical help in advancing your drug discovery or diagnostics programs, reach out to us at mark.fortner@aspenbiosciences.com.